Long-term amrinone therapy in patients with severe heart failure. Drug-dependent hemodynamic benefits despite progression of the disease

C. S. Maskin, Robert Forman, N. A. Klein, E. H. Sonnenblick, T. H. LeJemtel

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks). At initiation of therapy, the cardiac index increased from 1.74 ± 0.31 to 2.62 ± 0.52 (mean ± SD) liters/min/m2 (p < 0.01) and pulmonary capillary wedge pressure decreased from 26.5 ± 3.5 to 19.5 ± 5.4 mm Hg (p < 0.05). Symptoms were alleviated and exercise capacity increased from 5.9 ± 3.9 to 11.5 ± 4.5 minutes (p < 0.05). During long-term therapy, exercise capacity remained constant in three patients whereas it decreased in three others. All patients demonstrated an increase in heart size. Withdrawal of amrinone therapy precipitated severe symptoms at rest and hemodynamic deterioration in all patients. The cardiac index decreased from 1.87 ± 0.49 to 1.32 ± 0.30 liter/min/m2 (p < 0.05) and pulmonary capillary wedge pressure rose from 20.6 ± 2.9 to 28.8 ± 5.6 mm Hg (p < 0.05). These changes were reversed by reinstitution of therapy. Thus, amrinone-dependent hemodynamic benefits were demonstrated during long-term therapy without tachyphylaxis. In addition, progression of the underlying cardiac disease was observed in every patient.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalAmerican Journal of Medicine
Volume72
Issue number1
DOIs
StatePublished - 1982

Fingerprint

Amrinone
Disease Progression
Heart Failure
Hemodynamics
Pharmaceutical Preparations
Pulmonary Wedge Pressure
Therapeutics
Exercise
Tachyphylaxis
Vasodilator Agents
Heart Diseases

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Long-term amrinone therapy in patients with severe heart failure. Drug-dependent hemodynamic benefits despite progression of the disease. / Maskin, C. S.; Forman, Robert; Klein, N. A.; Sonnenblick, E. H.; LeJemtel, T. H.

In: American Journal of Medicine, Vol. 72, No. 1, 1982, p. 113-118.

Research output: Contribution to journalArticle

@article{aae1c3323e8546d18220785a4771c993,
title = "Long-term amrinone therapy in patients with severe heart failure. Drug-dependent hemodynamic benefits despite progression of the disease",
abstract = "Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks). At initiation of therapy, the cardiac index increased from 1.74 ± 0.31 to 2.62 ± 0.52 (mean ± SD) liters/min/m2 (p < 0.01) and pulmonary capillary wedge pressure decreased from 26.5 ± 3.5 to 19.5 ± 5.4 mm Hg (p < 0.05). Symptoms were alleviated and exercise capacity increased from 5.9 ± 3.9 to 11.5 ± 4.5 minutes (p < 0.05). During long-term therapy, exercise capacity remained constant in three patients whereas it decreased in three others. All patients demonstrated an increase in heart size. Withdrawal of amrinone therapy precipitated severe symptoms at rest and hemodynamic deterioration in all patients. The cardiac index decreased from 1.87 ± 0.49 to 1.32 ± 0.30 liter/min/m2 (p < 0.05) and pulmonary capillary wedge pressure rose from 20.6 ± 2.9 to 28.8 ± 5.6 mm Hg (p < 0.05). These changes were reversed by reinstitution of therapy. Thus, amrinone-dependent hemodynamic benefits were demonstrated during long-term therapy without tachyphylaxis. In addition, progression of the underlying cardiac disease was observed in every patient.",
author = "Maskin, {C. S.} and Robert Forman and Klein, {N. A.} and Sonnenblick, {E. H.} and LeJemtel, {T. H.}",
year = "1982",
doi = "10.1016/0002-9343(82)90589-7",
language = "English (US)",
volume = "72",
pages = "113--118",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term amrinone therapy in patients with severe heart failure. Drug-dependent hemodynamic benefits despite progression of the disease

AU - Maskin, C. S.

AU - Forman, Robert

AU - Klein, N. A.

AU - Sonnenblick, E. H.

AU - LeJemtel, T. H.

PY - 1982

Y1 - 1982

N2 - Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks). At initiation of therapy, the cardiac index increased from 1.74 ± 0.31 to 2.62 ± 0.52 (mean ± SD) liters/min/m2 (p < 0.01) and pulmonary capillary wedge pressure decreased from 26.5 ± 3.5 to 19.5 ± 5.4 mm Hg (p < 0.05). Symptoms were alleviated and exercise capacity increased from 5.9 ± 3.9 to 11.5 ± 4.5 minutes (p < 0.05). During long-term therapy, exercise capacity remained constant in three patients whereas it decreased in three others. All patients demonstrated an increase in heart size. Withdrawal of amrinone therapy precipitated severe symptoms at rest and hemodynamic deterioration in all patients. The cardiac index decreased from 1.87 ± 0.49 to 1.32 ± 0.30 liter/min/m2 (p < 0.05) and pulmonary capillary wedge pressure rose from 20.6 ± 2.9 to 28.8 ± 5.6 mm Hg (p < 0.05). These changes were reversed by reinstitution of therapy. Thus, amrinone-dependent hemodynamic benefits were demonstrated during long-term therapy without tachyphylaxis. In addition, progression of the underlying cardiac disease was observed in every patient.

AB - Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks). At initiation of therapy, the cardiac index increased from 1.74 ± 0.31 to 2.62 ± 0.52 (mean ± SD) liters/min/m2 (p < 0.01) and pulmonary capillary wedge pressure decreased from 26.5 ± 3.5 to 19.5 ± 5.4 mm Hg (p < 0.05). Symptoms were alleviated and exercise capacity increased from 5.9 ± 3.9 to 11.5 ± 4.5 minutes (p < 0.05). During long-term therapy, exercise capacity remained constant in three patients whereas it decreased in three others. All patients demonstrated an increase in heart size. Withdrawal of amrinone therapy precipitated severe symptoms at rest and hemodynamic deterioration in all patients. The cardiac index decreased from 1.87 ± 0.49 to 1.32 ± 0.30 liter/min/m2 (p < 0.05) and pulmonary capillary wedge pressure rose from 20.6 ± 2.9 to 28.8 ± 5.6 mm Hg (p < 0.05). These changes were reversed by reinstitution of therapy. Thus, amrinone-dependent hemodynamic benefits were demonstrated during long-term therapy without tachyphylaxis. In addition, progression of the underlying cardiac disease was observed in every patient.

UR - http://www.scopus.com/inward/record.url?scp=84886612624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886612624&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(82)90589-7

DO - 10.1016/0002-9343(82)90589-7

M3 - Article

C2 - 7058816

AN - SCOPUS:84886612624

VL - 72

SP - 113

EP - 118

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -